Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Sponsor: Centre Hospitalier de Lens (Co-Sponsor)
Listed as NCT01788020, this PHASE3 trial focuses on Waldenström's Macroglobulinemia and remains completed. Sponsored by Centre Hospitalier de Lens (Co-Sponsor), it has been updated 12 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Jun 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier de Lens (Co-Sponsor)
- University of Ulm
For direct contact, visit the study record on ClinicalTrials.gov .